Literature DB >> 34790965

Evaluation of an Initiation Regimen of Warfarin for International Normalized Ratio Target 2.0 to 3.0.

Sahimi Mohamed1, Chan Mei Fong1, Yew Jie Ming1, Ahlam Naila Kori1, Sopian Abdul Wahab1, Zarina Mohd Ali2.   

Abstract

Background: he number of patients on warfarin therapy is rising steadily. Although warfarin is beneficial, it carries a high risk of bleeding, especially if the international normalized ratio (INR) values exceed 3.0. Currently, no warfarin initiation regimens have been developed for the Asian population, especially for Malaysians. Objective: This article describes the efficacy and safety of a new initiation regimen for warfarin among warfarin-naive patients. Method: Data were retrospectively collected from the ambulatory and inpatient settings.
Results: A total of 165 patients who each had a target INR of 2.0 to 3.0 were included in the study. The mean age was 57.2 years and 94 patients were male. A total of 108 patients used Regimen 1 (5 mg/5 mg/3mg) and the rest of the patients used Regimen 2 (5 mg/3 mg/3 mg). Most patients used warfarin either for atrial fibrillation (52.1%) or for venous thromboembolism (29.7%). Overall, 88 of the patients had INR values above 50% from the baseline on Day 4. Additionally, 13 patients had INR values of >3.2, which required withholding and lower dose of warfarin. The predicted weekly maintenance warfarin dose (23 ± 0.5 mg/week) was found to have correlated closely with the actual maintenance dose (22.8 ± 0.5 mg/week; r 2 = 0.75). Nearly two thirds (70.3%) of the patients achieved the target INR on Day 11.
Conclusion: The warfarin initiation regimens in this study was simple, safe, and suitable to be used in both ambulatory and inpatient settings for managing warfarin therapy.
© The Author(s) 2021.

Entities:  

Keywords:  INR; ambulatory; atrial fibrillation; initiation; inpatients; venous thromboembolism; warfarin

Year:  2021        PMID: 34790965      PMCID: PMC8592241          DOI: 10.1177/87551225211034175

Source DB:  PubMed          Journal:  J Pharm Technol        ISSN: 1549-4810


  19 in total

1.  Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency.

Authors:  T P Baglin; D Cousins; D M Keeling; D J Perry; H G Watson
Journal:  Br J Haematol       Date:  2006-11-20       Impact factor: 6.998

2.  Why warfarin and heparin need to overlap when treating acute venous thromboembolism.

Authors:  Ann K Wittkowsky
Journal:  Dis Mon       Date:  2005 Feb-Mar       Impact factor: 3.800

3.  Standardised initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomised trial, and risk factors for an excessive warfarin response.

Authors:  C J Doecke; D G Cosh; A S Gallus
Journal:  Aust N Z J Med       Date:  1991-06

Review 4.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J E Dalen; D R Anderson; L Poller; H Bussey; J Ansell; D Deykin; J T Brandt
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

5.  Flexible induction dose regimen for warfarin and prediction of maintenance dose.

Authors:  A Fennerty; J Dolben; P Thomas; G Backhouse; D P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-28

6.  Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.

Authors:  L Harrison; M Johnston; M P Massicotte; M Crowther; K Moffat; J Hirsh
Journal:  Ann Intern Med       Date:  1997-01-15       Impact factor: 25.391

7.  Warfarin induction at 5 mg daily is safe with a low risk of anticoagulant overdose: results of an audit of patients with deep vein thrombosis commencing warfarin.

Authors:  P Harper; K Monahan; B Baker
Journal:  Intern Med J       Date:  2005-12       Impact factor: 2.048

8.  Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.

Authors:  Virginie Siguret; Isabelle Gouin; Matthieu Debray; Christine Perret-Guillaume; Jacques Boddaert; Isabelle Mahé; Valérie Donval; Marie-Laure Seux; Marjolaine Romain-Pilotaz; Mathilde Gisselbrecht; Marc Verny; Eric Pautas
Journal:  Am J Med       Date:  2005-02       Impact factor: 4.965

9.  The risk of hemorrhage among patients with warfarin-associated coagulopathy.

Authors:  David A Garcia; Susan Regan; Mark Crowther; Elaine M Hylek
Journal:  J Am Coll Cardiol       Date:  2006-01-26       Impact factor: 24.094

10.  A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation.

Authors:  R C Tait; A Sefcick
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.